



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 35/74	A1	(11) International Publication Number: WO 96/26732 (43) International Publication Date: 6 September 1996 (06.09.96)
(21) International Application Number: PCT/EP96/00558 (22) International Filing Date: 9 February 1996 (09.02.96) (30) Priority Data: MI95A000378 28 February 1995 (28.02.95) IT (71) Applicant (for all designated States except US): NEW-PHARMA S.R.L. [IT/IT]; Via Mecenate, 76, I-20138 Milano (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): RONCHI, Celestino [IT/IT]; Via G. Galilei, 7, I-20016 Pero (IT). BERLATI, Fabio [IT/IT]; Via G. Galilei, 7, I-20016 Pero (IT). (74) Agent: BIANCHETTI, Giuseppe; Studio Consulenza Brevetuale, Via Rossini, 8, I-20122 Milano (IT).		(81) Designated States: JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS OF LACTIC ACID BACTERIA AND SACCHAROMYCES LYSATES AND THE THERAPEUTICAL USE THEREOF (57) Abstract Combinations of lactic acid bacteria and Saccharomyces lysates are described having immunostimulating activity, the use thereof in human and veterinary medicine and pharmaceutical compositions containing them.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

COMPOSITIONS OF LACTIC ACID BACTERIA AND SACCHAROMYCES LYSATES AND THE THERAPEUTICAL USE THEREOF

The present invention relates to combinations of lactic acid bacteria and Saccharomyces lysates and/or glucans, the use thereof as immunostimulating agents and pharmaceutical compositions containing them.

5 Technological background

Lactic Acid Bacteria, hereinafter referred to as LAB, which comprise, inter alia, Lactobacilli (among which Acidophylus, Bulgaricus, Delbreukii, Fermentum, Casei), Streptococci (among them, Thermophylus),
10 Bifidobacteria (Longum, Biphydus, Pullorum, inter alia) and sporogenous lactobacilli, such as Lactobacillus sporogenes, have been used for a long time in pharmaceutical, dietetic or food products and administered to restore bacteria flora in dysmicrobisms
15 of various nature, for example due to antibiotic therapies or to diseases of the gastro-intestinal tract (Bottazzi, Zacconi, Sarra, Probiotica con Batteri Lattici, Centro Sperimentale del Latte, Milan, Italy). LAB, besides being a direct source of Vitamins of the
20 groups B, D, K, and the like, act through a mechanism of competitive antagonism against microorganisms, pathogenic and/or opportunists, which, in particular conditions, have affected the normal intestinal bacterial flora (Bottazzi, Zacconi, Sarra, Probiotica
25 con Batteri Lattici, Centro Sperimentale del Latte, Milan, Italy).

Bacteria are known to have (Sharon et Lis,

Carbohydrates in Cell recognition - Sci. Am.-Jan. 93) a cell wall characterized by the presence of specific polysaccharides which allow for the bacterium itself to adhere to the intestinal epythelium, the latter being characterized in turn by analogue polysaccharide receptors. The presence of said receptor sites contributes to establish the antagonism among the various bacteria, when the micro-climatic conditions vary (pH, redox potential).

10 The polysaccharides present on the cell walls are of different nature, but polysaccharides deriving from mannan, characterized by α 1-6, 1-2 and 1-3 bonds, from glucans (β 1-3 polyglucose) are always present.

It is known that mannans (Technical Publication n. 15 113 Alltech Inc. Nicholasville, KY, U.S.A.) can be used to favourably change the intestinal ecosystem by competitively inhibiting the adhesion sites which could be used as adhesion and colonization points by pathogenic microorganisms. Fructans and glucans 20 (polyfructose and polyglucose, respectively) were employed as an alternative to mannans, with the same purposes. Fructans turned out to be easily fermentable by a great number of microorganisms which on the contrary cannot hydrolyse glucans (only some species of 25 microorganisms can hydrolyse and ferment glucans).

Moreover, mannans are known (Technical Publication n. 113 Alltech Inc. Nicholasville, KY, U.S.A.) to have a strong stimulating action in the growth of such LAB as Bifidobacteria, Lactic acid bacteria and Streptococci.

30 Disclosure of the invention

It has surprisingly been found that, upon

administration of a combination of LAB and Saccharomyces lysates containing glucans for the treatment of intestinal dysmicrobiosis, a significant increase in all of the blood elements, both formed and non formed, involved in the non-specific immune response (macrophages, lymphocytes etc.) takes place.

Therefore, it is an object of the present invention a combination comprising:

- a) lactic acid bacteria;
- b) Saccharomyces lysates; and optionally
- c) glucans,

being it possible to replace component b) with component c).

It is another object of the present invention the use of the combination as an immunostimulating agent.

It is still another object of the present invention the use of the combination as an active ingredient, optionally in the presence of other pharmacological agents, for the manufacture of a medicament useful to improve immune defences in man and in animals.

A further object of the present invention is provided by pharmaceutical compositions containing the combination as the active ingredient.

Detailed disclosure of the invention

According to the present invention, lactic acid bacteria or LAB, as herein meant, comprise lactic acid bacteria in a broad sense. Examples of LABs are Lactobacillus acidophylus, L. bulgaricus, L. delbreukii, L. casei, L. Fermentum, the Streptococcus genus, for example S. thermophylus, Bifidobacteria, such as B. longum, B. biphidus, B. pullorum, the sporogenous genus,

for example Lactobacillus sporogenes.

The Saccharomyces lysates can be obtained by methods known to those skilled in the art, see for instance J. A. Reynolds et al., Infection and Immunity, 5 Oct. 1980, vol. 30, n. 1, p. 51-57 and the literature therein cited.

Glucans of different purity can be obtained by known methods and are also commercially available.

According to the present invention, the ratio of 10 component a) to component b), the latter optionally in admixture with component c), or of component a) to component c), ranges from 1:1,000 to 1:0.001.

According to a first preferred embodiment of the present invention, the lysate is obtained from 15 Saccharomyces cerevisiae.

According to another preferred embodiment of the present invention, the LAB is selected from the group consisting of L. acidophylus, L. bulgaricus, or a combination thereof, L. thermophylus.

20 The immunostimulating action of glucan being known (J. A. Reynolds et al. - Glucan-Induced Enhancement of Host Resistance to Selected Infectious Diseases, Infect. et Immun. 30, 1, 51-57 - Oct. 1980) (Kokoshis et al. - Increased Resistance to Staphylococcus aureus Infection and Enhancement in Serum Lysozyme Activity by Glucan - 25 Scie. 199, March 24, 1978), the action on the immune system of the single components of the combination (LAB and Saccharomyces cerevisiae lysates) was evaluated.

Thus, the immunostimulating action induced by the 30 combination of LAB and Saccharomyces cerevisiae lysate and/or glucans was evidenced to be substantially higher

5

than that found in the subjects treated with only Saccharomyces lysates (glucans) ~> 15%) and with LAB only (> 70%). The actions exerted by Saccharomyces cerevisiae lysate and that of glucans were not substantially different.

Further controls proved that, in the treated subjects, the immune responses from subjects treated with only glucan and/or Saccharomyces lysate are statistically different from those obtained in subjects treated with the combinations of the two products. In fact, an increase in macrophages, as well as the presence of lymphocytes joined to an increase in lysozyme production moreover shown by the increase in the development of the cell endoplasmic reticulum.

The oral administration of a combination of Saccharomyces cerevisiae lysates and/or glucans with LAB proved to be a simple, effective means to improve immune defenses in man and animals.

Such an administration can be carried out by use of pharmaceutical compositions containing the combination of the invention in admixture with conventional carriers and excipients. The compositions can be solid, such as tablets (prompt-release or controlled-released ones), coated tablets (film-coated, gastro-resistant, controlled-release, sugar-coated pills), effervescent or fast-dissolution tablets, chewable tablets, soft- and hard-gelatin capsules, sugar-coated pills; or they can be liquid, such as solutions, suspensions, syrups, elixirs, granulates for suspensions or solutions to be reconstituted.

The compositions according to the invention can be

prepared with techniques known to those skilled in the art, for example as described in "Remington's Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A..

5 The daily dosages will be established by the physician, depending on the disease to treat and the conditions of the patient (age, sex, weight).

By way of examples, the doses can range as follows:

LAB: 1 million of c.f.u./dose to 100 billion of
10 c.f.u./dose;

Saccharomyces lysates: 0.1 mg/dose to 1 g/dose;

glucans: 0.1 mg/dose to 1 g/dose.

The daily dose can vary from 1 dose/day to 5 doses/day.

15 According to the present invention, the compositions and the medicaments can be used both in human and veterinary medicines.

The compositions of the invention for the improvement of the immune responses in man and animals
20 can be used not only for therapeutic, but also for prophylactic purposes. For the latter, besides the above mentioned pharmaceutical compositions, the present invention also comprises dietetic and food compositions containing the combination described above.

25 The following examples further illustrate the invention.

Example 1

Capsules

One capsule contains:

30	Lactobacilli Acidophylus and Bulgaricus	10 billion
	Saccharomyces lysates	100 mg

7

	Lactose	500 mg
	Magnesium Stearate	20 mg
	Capsule coating:	
	Food gelatin	
5	Titanium dioxide.	

Example 2

Tablets

One tablet contains:

	Lactobacilli Acidophylus and Bulgaricus	20 billion
10	Saccharomyces lysates	300 mg
	Microcrystalline cellulose	600 mg
	Talc	20 mg
	Magnesium Stearate	10 mg

Example 3

15 Granulate sachets

One dosage unit contains:

	Lactobacillus Thermophylus	10 billion
	Saccharomyces lysates	100 mg
	Saccharose	5,000 mg
20	Orange flavour	30 mg

Example 4

Vials with dosage cap

Content of dosage cap:

	- Lactobacillus Sporogenes Spores	500 million
25	- Lactobacillus Thermophylus	500 million

Contents of vial:

	- <u>Saccharomyces C.</u> lysates	200 mg
	- Saccharose	2 g
	- Methyl-p-hydroxybenzoate	0.0075 mg
30	- Depurated water	q.s. to ml 5.

CLAIMS

1. Combinations comprising:
 - a) lactic acid bacteria
 - 5 b) *Saccharomyces* lysates, and optionally
 - c) glucans,being it possible to replace component b) with component c).
2. Combinations according to claim 1, wherein the
10 lactic acid bacteria are selected from the group comprising the genera *Lactobacillus*, *Streptococcus*, *Bifidobacteria* and sporogenous lactobacilli.
3. Combinations according to claim 2, wherein the
15 *Lactobacillus acidophylus*, *L. bulgaricus*, *L. delbreukii*, *L. casei*, *L. Fermentum*, or combinations thereof.
4. Combinations according to claim 2, wherein the *Streptococcus* is *S. thermophilus*.
5. Combinations according to claim 2, wherein the
20 Sporogenous is *Lactobacillus Sporogenes* spores.
6. A combination according to claim 2, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum*, *B. biphydus*, *B. pullorum* o combinations thereof.
- 25 7. Combinations according to any one of the above claims, wherein the ratio of component a) to component b), the latter optionally in admixture with component c), or of component a) to component c), ranges from 1:1,000 to 1:0.001.
- 30 8. Combinations according to any one of the above claims, wherein the lysate is obtained from

Saccharomyces cerevisiae.

9. The use of the combinations of claims 1-8 as immunostimulating agents.

10. The use of the combinations of claims 1-8 as active ingredient for the preparation of a medicament useful for the improvement of the immune defenses for the therapeutical or prophylactic purposes in man and animals.

11. Pharmaceutical compositions containing as the active ingredient the combinations of claims 1-8 in admixture with conventional carriers and excipients.

12. Compositions according to claim 11, selected from the group consisting of prompt-release tablets, controlled-release tablets, coated tablets, sugar-coated pills, effervescent or fast-dissolution tablets, chewable tablets, soft- and hard-gelatin capsules.

13. Compositions according to claim 11, selected from the group consisting of solutions, suspensions, syrups, elixirs, granulates for suspensions or solutions to be reconstituted.

14. A pharmaceutical composition in the form of capsules according to the claims 11-12, comprising for each capsule:

Lactobacilli Acidophylus and Bulgaricus	10 billion
Saccharomyces lysates	100 mg
Lactose	500 mg
Magnesium Stearate	20 mg

Capsule coating:

Food gelatin

30 Titanium dioxide.

15. A pharmaceutical composition in the form of tablet

10

according to the claims 11-12, comprising for each tablet:

	Lactobacilli Acidophylus and Bulgaricus	20 billion
	Saccharomyces lysates	300 mg
5	Microcrystalline cellulose	600 mg
	Talc	20 mg
	Magnesium Stearate	10 mg.

16. A pharmaceutical composition in the form of granulate according to the claims 11-12, comprising for unitary dose:

	Lactobacillus Thermophylus	10 billion
	Saccharomyces lysates	100 mg
	Saccharose	5,000 mg
	Orange flavour	30 mg.

15 17. A pharmaceutical composition in the form of vials with reservoir plug according to the claims 11-12, comprising:

Content of dosage cap:

	- Lactobacillus Sporogenes Spores	500 million
20	- Lactobacillus Thermophylus	500 million

Contents of vial:

	- <u>Saccharomyces C.</u> lysates	200 mg
	- Saccharose	2 g
	- Methyl-p-hydroxybenzoate	0.0075 mg
25	- Depurated water	q.s. to ml 5.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/00558

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K35/74

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	FR,A,2 718 752 (WORLD TRUST INVESTMENT) 20 October 1995 see claims 1,12 see page 5; example 1 see page 24, line 4 - line 34 ---	1-17
X	PATENT ABSTRACTS OF JAPAN vol. 17, no. 394 (C-1088) & JP,A,05 076292 (MARUTA KIYOSHI), 3 March 1993, see abstract ---	1-17
X	EP,A,0 396 744 (KABUSHIKI KAISYA ADVANCE) 14 November 1990 see claims 1,6 see page 10, line 1 - page 11, line 5 see page 12, line 3 - line 5 ---	1-8, 11-17
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

3 July 1996

Date of mailing of the international search report

16.07.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patendaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Gerli, P

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 96/00558

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IT,B,1 239 743 (GORKI EPIDEMIOLOG. MICROBIOLOG. INST.) 15 November 1993 see page 13, line 4 - line 14 see page 14; example 1 ---	1-8, 11-17
Y	INFECT. IMMUN., vol. 30, no. 1, 1980, pages 51-57, XP000574740 "Glucan-induced enhancement of host resistance to selected infectious diseases" cited in the application see page 51 ---	1-17
Y	WO,A,94 26114 (IMMUNOM TECHNOLOGIES INC.) 24 November 1994 see claim 1 see page 19, line 8 - line 13 ---	1-17
Y	WO,A,89 11858 (WITECHLIFFE LAB.) 14 December 1989 see page 3, line 1 - line 14 -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 96/00558

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-2718752	20-10-95	FR-A- 2718751	20-10-95
EP-A-396744	14-11-90	DE-D- 3885468	09-12-93
		DE-T- 3885468	24-02-94
		WO-A- 8900425	26-01-89
IT-B-1239743	15-11-93	NONE	
WO-A-9426114	24-11-94	NONE	
WO-A-8911858	14-12-89	AU-B- 3836489	05-01-90